Barcelona, Spain

Time filter

Source Type

Virgili N.,Neurotec Pharma | Mancera P.,Neurotec Pharma | Wappenhans B.,Neurotec Pharma | Sorrosal G.,Advancell | And 4 more authors.
PLoS ONE | Year: 2013

Pharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection. For instance, diazoxide, a well-known ATP-sensitive potassium channel activator with high affinity for mitochondrial component of the channel has been proved to be effective in animal models for different diseases such as Alzheimer's disease, stroke or multiple sclerosis. Here, we analyzed the ability of diazoxide for protecting neurons front different neurotoxic insults in vitro and ex vivo. Results showed that diazoxide effectively protects NSC-34 motoneurons from glutamatergic, oxidative and inflammatory damage. Moreover, diazoxide decreased neuronal death in organotypic hippocampal slice cultures after exicitotoxicity and preserved myelin sheath in organotypic cerebellar cultures exposed to pro-inflammatory demyelinating damage. In addition, we demonstrated that one of the mechanisms of actions implied in the neuroprotective role of diazoxide is mediated by the activation of Nrf2 expression and nuclear translocation. Nrf2 expression was increased in NSC- 34 neurons in vitro as well as in the spinal cord of experimental autoimmune encephalomyelitis animals orally administered with diazoxide. Thus, diazoxide is a neuroprotective agent against oxidative stress-induced damage and cellular dysfunction that can be beneficial for diseases such as multiple sclerosis. © 2013 Virgili et al.


News Article | December 10, 2016
Site: marketersmedia.com

— Stroke Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, Acticor Biotech, ActiveSite Pharmaceuticals Inc, Addex Therapeutics Ltd, advanceCor GmbH, Affibody AB, Amarantus Bioscience Holdings Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Antoxis Ltd, APT Therapeutics, Inc., ArmaGen Inc, Asterias Biotherapeutics, Inc., AstraZeneca Plc, Athersys Inc, Bayer AG, Bioasis Technologies Inc, Biogen Inc, Boehringer Ingelheim GmbH, Cardax Inc, Cellular Biomedicine Group Inc, CHA Bio & Diostech Co Ltd, ContraVir Pharmaceuticals Inc, CSPC Pharmaceutical Group Limited, D-Pharm Ltd, Daiichi Sankyo Company Ltd, DiaMedica Inc, Diffusion Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fina Biotech, Genervon Biopharmaceuticals LLC, Glialogix Inc, Glucox Biotech AB, Green Cross Corp, Huons Co Ltd, International Stem Cell Corp, Jeil Pharmaceutical Co Ltd, JN-International Medical Corp, Laboratoires Pierre Fabre SA, LegoChem Biosciences Inc, Les Laboratoires Servier SAS, Living Cell Technologies Ltd, Lumosa Therapeutics Co Ltd, M et P Pharma AG, Magnus Life Ltd, Mapreg SAS, Mast Therapeutics Inc, Medestea Research & Production SpA, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neurofx Inc, Neuronax SAS, Neurotec Pharma SL, NeuroVive Pharmaceutical AB, New Haven Pharmaceuticals, Inc., New World Laboratories Inc, NoNO Inc, NuvOx Pharma LLC, Omeros Corp, Panacea Pharmaceuticals Inc, PharmatrophiX, Inc., Pharmaxis Ltd, Pharmicell Co Ltd, Phoenix Biotechnology Inc, Phylogica Ltd, PhytoHealth Corp, Pluristem Therapeutics Inc, Primary Peptides, Inc., Q Therapeutics Inc, QR Pharma Inc, ReCyte Therapeutics Inc, Regenera Pharma Ltd, RegeneRx Biopharmaceuticals Inc, Remedy Pharmaceuticals Inc, ReNeuron Group Plc, SanBio Inc, Saneron CCEL Therapeutics Inc, Shin Poong PharmCo Ltd, Simcere Pharmaceutical Group, Stemedica Cell Technologies Inc, SynZyme Technologies LLC, Targazyme Inc, The International Biotechnology Center (IBC) Generium, TikoMed AB, vasopharm GmbH, Verseon Corp, Vicore Pharma AB, Virogenomics BioDevelopment Inc, WhanIn Pharmaceutical Co Ltd and Zocere Inc. This research provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774104 The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively. Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774104 • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular). • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774104-stroke-pipeline-review-h2-2016.html


— Amyotrophic Lateral Sclerosis Pipeline Market Companies Involved in Therapeutics Development are 2-BBB Medicines BV, AB Science SA, Aestus Therapeutics Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Apodemus AB, Apogenix GmbH, Apotex Inc, ArmaGen Inc, BioCrea GmbH, Biogen Inc, Biohaven Pharmaceutical Holding Company Limited, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Calico LLC, Catabasis Pharmaceuticals Inc, Cellceutix Corp, Chronos Therapeutics Ltd, ContraVir Pharmaceuticals Inc, Corcept Therapeutics Inc, Curatis Pharma GmbH, Cytokinetics Inc, Daval International Ltd, Edison Pharmaceuticals Inc, Eisai Co Ltd, Ensemble Therapeutics Corp, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma, Inc., FPRT Bio Inc, Gemac, Genentech Inc, Genervon Biopharmaceuticals LLC, GeNeuro SA, GenKyoTex SA, Glialogix Inc, Grifols SA, Herantis Pharma Plc, ImStar Therapeutics Inc., InFlectis BioScience, Ionis Pharmaceuticals Inc, Italfarmaco SpA, Jeil Pharmaceutical Co Ltd, Kadimastem Ltd, Karyopharm Therapeutics Inc, KineMed Inc, Kringle Pharma Inc, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Lascco SA, Lead Discovery Center GmbH, M's Science Corp, Maas Biolab, Mallinckrodt Plc, MedDay SA, MeiraGTx Limited, miCure Therapeutics Ltd., miRagen Therapeutics Inc, MitoDys Therapeutics Limited, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neurimmune Holding AG, Neurotec Pharma SL, Neurotune AG, Orion Oyj, Orphazyme ApS, Pharnext SA, Plex Pharmaceuticals Inc, Prevacus Inc, Primary Peptides, Inc., ProMIS Neurosciences Inc, Q Therapeutics Inc, ReceptoPharm Inc, Regenesance BV, reMYND NV, Saneron CCEL Therapeutics Inc, SciFluor Life Sciences LLC, SK Biopharmaceuticals Co Ltd, Spherium Biomed SL, Symic Biomedical Inc, Teva Pharmaceutical Industries Ltd, Thera Neuropharma Inc, Treeway BV, Valeant Pharmaceuticals International Inc, ViroMed Co Ltd, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, WAVE Life Sciences Ltd and Yooyoung Pharmaceutical Co Ltd. This research provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774107 The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively. Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774107 • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774107-amyotrophic-lateral-sclerosis-pipeline-review-h2-2016.html


Patent
Natac Biotech S.L. and Neurotec Pharma | Date: 2014-12-17

The present invention is related to a product comprising a pentacyclic triterpene and hydroxytyrosol or derivatives thereof, uses, and pharmaceutical composition thereof.


The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), clinically isolated syndrome (CIS), tumefactive (tumor-like) M S, Marburgs acute M S, Balss concentric sclerosis, acute disseminated encephalomyelitis (ADEM), post-vaccinal encephalitis (PVE), post-infectious encephalomyelitis (PIE) and neuromyelitis optica (NMO).


The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis.


The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis.


The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and post-vaccinal encephalitis (PVE).


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/76wm2g/ischemic_cerebral) has announced the addition of the "Ischemic Cerebral Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Cerebral Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Cerebral Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Loading Neurotec Pharma collaborators
Loading Neurotec Pharma collaborators